{
"id":"mk19_b_gm_t30",
"number":30,
"bookId":"gm2",
"title":{
"__html":"Recommendations for Perioperative Bridging in Patients With Venous Thromboembolism Requiring Interruption of Vitamin K Antagonist Therapy"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"7c62f3",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 30. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_gm_t30"
}
]
},
"Recommendations for Perioperative Bridging in Patients With Venous Thromboembolism Requiring Interruption of Vitamin K Antagonist Therapy"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cd88de",
"class":"col hd l",
"children":[
"Risk for Thromboembolism"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c623fc",
"class":"col hd l",
"children":[
"Patient History"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8191d7",
"class":"col hd l",
"children":[
"Bridging Anticoagulation Recommendation"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9f8d6d",
"class":"cell txt l",
"children":[
"High (annual risk >10%)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"402f17",
"class":"cell txt l",
"children":[
"Recent (within 3 mo) VTE"
]
},
" ",
{
"type":"p",
"hlId":"cfe38f",
"class":"cell txt l",
"children":[
"Severe thrombophilia (e.g., deficiency of protein C, protein S, or antithrombin; antiphospholipid antibodies; multiple thrombophilic abnormalities)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eac98d",
"class":"cell txt l",
"children":[
"Bridging"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"67484d",
"class":"cell txt l",
"children":[
"Moderate (annual risk of 5%-10%)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7694b3",
"class":"cell txt l",
"children":[
"VTE within the past 3-12 mo"
]
},
" ",
{
"type":"p",
"hlId":"94c12d",
"class":"cell txt l",
"children":[
"Nonsevere thrombophilia (e.g., heterozygous factor V Leiden or prothrombin gene mutation)"
]
},
" ",
{
"type":"p",
"hlId":"49e913",
"class":"cell txt l",
"children":[
"Recurrent VTE"
]
},
" ",
{
"type":"p",
"hlId":"48b8bf",
"class":"cell txt l",
"children":[
"Active cancer (treated within 6 mo or palliative)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"16c768",
"class":"cell txt l",
"children":[
"No bridging"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5f4227",
"class":"cell txt l",
"children":[
"Low (annual risk <5%)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"86f430",
"class":"cell txt l",
"children":[
"VTE >12 mo ago and no other risk factors"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"16c768",
"class":"cell txt l",
"children":[
"No bridging"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"VTE = venous thromboembolism."
],
[
"Recommendations from Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018;2:3257-91. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30482765",
"target":"_blank"
},
"children":[
"PMID: 30482765"
]
},
" doi:10.1182/bloodadvances.2018024893 ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"and"
]
},
" Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e227S-e277S. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/22315263",
"target":"_blank"
},
"children":[
"PMID: 22315263"
]
},
" doi:10.1378/chest.11-2297"
]
]
}